Steve Willoughby

About Steve Willoughby

Steve Willoughby is an accomplished Senior Vice President of Investor Relations, ESG, EHS, and Corporate Risk Management for Revvity, with 20+ years of experience driving strategic business development, corporate strategy, and corporate communications in high-growth environments across diverse industries. He transforms business strategy, functions, and infrastructures across core organizational pillars, including Investor Relations, ESG, EHS, Corporate Risk Management, Communications, and Stock Administration, with an unyielding commitment to excellence at every level. He leverages a proactive, high-touch approach with deep financial acumen to proactively position and own the narrative speaking to both the employee and investor mindset. Steve masters a collaborative leadership approach to effectively build consensus with global stakeholders and investment teams across large business initiatives. Investor Relations Strategy + Communications Global ESG Strategy + Vision Corporate Risk Management + Corporate Insurance Stock Administration M&A and Business Development Strategy Board Governance & Structuring + 2x IR Magazine Investor Relations Officer of the Year Finalist (2024, 2023) Multi-category IR Magazine Award Nominee (Revvity): Best Investor Event (2025), Best in Healthcare sector (2025), Best IR During a Corporate Transition (2024), Best IR Website (2024) Launched Revvity (RVTY) on the NYSE (2023) Inaugural Head of ESG of Revvity Executed the $5.25B acquisition of BioLegend & $2.3B divestiture of Perkin & Elmer (Revvity) Thomas Reuters 2018 #1 Stock Picker for Life Science Tools & Services Sector Cleveland Research Company (CRC) Founding Member Partner“.” –

Experience

1. Senior Vice President of Investor Relations, Esg & Corporate Risk Management

   Revvity

   Jan 2022 — Present · Waltham, MA, US

   Leads and owns complete Investor Relations strategy, ESG, Corporate Risk Management and Insurance, and Stock Administration for the ~$15bn market cap NYSE listed and S&P 500 company dedicated to life sciences and diagnostics, spanning over 190 countries. 2x Investor Relations Officer of the Year Finalist by IR Magazine Multi-category 2024 IR Magazine Award Nominee (Revvity): Best IR Website + Best IR During a Corporate Transition Launched Revvity (RVTY) on the NYSE Inaugural Head of ESG Executed the $5.25B acquisition of BioLegend & $2.3B divestiture of Perkin Elmer (Revvity): Leads Investor Relations Strategy, Investment Activities, Shareholder Targeting, and Investor Communications. Key participant in Strategy, Regulatory Compliance, Corporate Communications, and Business Development: Develops and integrates the complete ESG strategy, structures, compliance, and reporting into overall corporate strategy, LOBs, and 150 sites worldwide, including the U.S, China, India, Sweden, the UK, Germany, and Finland: Oversees the corporate and financial integrity and resilience of the organization, including insurance for Property and Casualty, Cyber Security, Medical Malpractice, Product Liability, Directors and Officers, and Business Travel: Collaboratively oversees the administration, implementation, regulatory compliance, and communication of 401k and employee pension plans.

Education

• Miami University Farmer School of Business

  Bachelor of Science, BS, Finance

  1999 — 2003

Skills

• Competitive Analysis
• Breast Augmentation
• Finance
• Pcr
• Healthcare
• Financial Analysis
• Leadership
• Strategic Planning
• Management
• Equity Valuation
• Financial Modeling
• Equity Research
• Forecasting
• Hplc
• Ophthalmology
• Pharmaceutical Industry
• Cosmetics
• Research
• Strategy
• Lifesciences
• Medical Devices
• Aesthetics
• Market Research
• Valuation
• Life Sciences
• Fundamental Research